Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MBX OTCMKTS:PFSCF NASDAQ:PGEN OTCMKTS:TRUU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBXMBX Biosciences$13.75+3.8%$12.25$4.81▼$27.50$459.58MN/A322,395 shs513,171 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/APGENPrecigen$1.67-2.3%$1.57$0.65▼$2.17$504.76M1.783.00 million shs2.02 million shsTRUUTrue Drinks$0.10$0.10$0.00▼$0.08$496.77M10.91.01 million shs3,892 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBXMBX Biosciences+3.77%-5.63%+11.52%+14.58%+1,374,999,900.00%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%PGENPrecigen-2.34%+6.37%+3.73%+6.37%+9.87%TRUUTrue Drinks0.00%0.00%+0.91%-4.63%-33.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBXMBX Biosciences2.6288 of 5 stars3.50.00.00.03.41.70.6PFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/APGENPrecigen3.9979 of 5 stars3.51.00.04.73.11.70.6TRUUTrue DrinksN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBXMBX Biosciences 3.00Buy$37.57173.25% UpsidePFSCFProMetic Life Sciences 0.00N/AN/AN/APGENPrecigen 3.00Buy$6.00259.28% UpsideTRUUTrue Drinks 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PFSCF, PGEN, TRUU, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.006/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBXMBX BiosciencesN/AN/AN/AN/AN/AN/APFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08PGENPrecigen$4.20M117.34N/AN/A$0.13 per share12.85TRUUTrue Drinks$1.95M254.76N/AN/A($0.03) per share-3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/APFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/APGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)TRUUTrue Drinks-$3.88M$0.019.99∞N/A-255.80%N/A-165.86%N/ALatest PFSCF, PGEN, TRUU, and MBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PGENPrecigen-$0.14N/AN/AN/A$0.67 millionN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBXMBX BiosciencesN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ATRUUTrue DrinksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBXMBX BiosciencesN/AN/AN/APFSCFProMetic Life SciencesN/A0.950.71PGENPrecigenN/A3.533.53TRUUTrue DrinksN/A0.01N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBXMBX BiosciencesN/APFSCFProMetic Life Sciences0.10%PGENPrecigen33.51%TRUUTrue DrinksN/AInsider OwnershipCompanyInsider OwnershipMBXMBX Biosciences52.19%PFSCFProMetic Life SciencesN/APGENPrecigen47.10%TRUUTrue Drinks18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBXMBX Biosciences3633.42 millionN/AN/APFSCFProMetic Life Sciences5023.31 millionN/ANot OptionablePGENPrecigen190295.18 million156.15 millionOptionableTRUUTrue Drinks404.97 billionN/ANot OptionablePFSCF, PGEN, TRUU, and MBX HeadlinesRecent News About These CompaniesTrue Drinks (OTCMKTS:TRUU) Share Price Passes Below 50-Day Moving Average - What's Next?July 23, 2025 | marketbeat.comTrue Drinks (OTCMKTS:TRUU) Share Price Crosses Below Fifty Day Moving Average - What's Next?July 15, 2025 | marketbeat.comBeer News: True Acts Of Aletruism / New “Indie Beer” CampaignNovember 13, 2024 | americancraftbeer.comAHow Much Alcohol Can You Drink a Week and Still Be Healthy?November 13, 2024 | msn.comStarbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional factsNovember 9, 2024 | msn.comCan You Drink Alcohol After Getting a COVID-19 Booster?October 29, 2024 | health.comHIt's True: Some Pizza Hut Locations Still Serve AlcoholOctober 22, 2024 | yahoo.comReview: True Story Finished BourbonOctober 21, 2024 | msn.comVitalizes Body and Mind.®October 4, 2024 | redbull.comR7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’October 2, 2024 | msn.com‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in itSeptember 21, 2024 | nypost.comNSeattle’s True Loves Drop a Funky New SingleAugust 31, 2024 | msn.comCannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinksAugust 31, 2024 | msn.comThese alcoholic drinks can raise the risk of gout, a painful type of arthritisAugust 30, 2024 | nypost.comN14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master MixologistAugust 29, 2024 | yahoo.com7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)August 25, 2024 | bbc.co.uk12 Unhealthiest Drinks You Should Think Twice About Ordering At A BarAugust 18, 2024 | msn.comTrue Loaf Bakery gets starter from two local bakersAugust 10, 2024 | msn.comPD TRUE : STREAM IT OR SKIP IT?August 6, 2024 | decider.comD10 Drinks People Fake Liking to Fit InAugust 5, 2024 | msn.com16 Best Summer Cocktails for a Hot Weather BuzzJuly 26, 2024 | esquire.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimePFSCF, PGEN, TRUU, and MBX Company DescriptionsMBX Biosciences NYSE:MBX$13.75 +0.50 (+3.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.72 -0.03 (-0.18%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Precigen NASDAQ:PGEN$1.67 -0.04 (-2.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.72 +0.05 (+2.93%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.True Drinks OTCMKTS:TRUU$0.10 0.00 (0.00%) As of 07/25/2025True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
